

April 27, 2023

News Release

J-Pharma Co., Ltd.

**At the 2023 ASCO Annual meeting, the latest information on the Japan Phase II study of *Nanvuranlat* (development code: JPH203) will be announced. *Nanvuranlat* is a novel L-type amino acid transporter 1 (LAT1) inhibitor for refractory biliary tract cancer patients.**

J-Pharma Co., Ltd. (Headquarters: Yokohama, Kanagawa; President & CEO: Max Yoshitake). *Nanvuranlat* is a novel low-molecular-weight compound that J-Pharma has independently created targeting L-type amino acid transporter 1 (LAT1). The latest information on the Japan Phase II trial of "*Nanvuranlat* (development code: JPH203)" for advanced refractory biliary tract cancer will be announced from the 2<sup>nd</sup> to 6<sup>th</sup> June 2023, in Chicago, Illinois, USA. Additional updates will be presented at the 2023 ASCO Annual Meeting.

1. Session Type/Title:  
Clinical Science Symposium - Target or TIGIT in Hepatobiliary Cancer
2. Session Date and Time:  
June 4, 2023 4:30 PM-6:00 PM (U.S. CDT)
3. Location:  
Arie Crown Theater
4. Abstract Number for Publication:  
4011
5. Abstract Title:  
Subgroup analysis of double-blind, placebo-controlled Phase II study of *Nanvuranlat* in pre-treated, advanced, refractory biliary tract cancer (BTC) patients with high LAT1 expression and the response to *Nanvuranlat*.
6. Presenter: (Oral presentation)  
Masafumi Ikeda, MD, PhD | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East